Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CTICNASDAQ:DYNNASDAQ:TBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/ADYNDyne Therapeutics$25.44+2.3%$26.00$6.40▼$30.27$2.19B0.951.99 million shs807,667 shsTBPHTheravance Biopharma$9.22-2.5%$9.03$8.21▼$11.98$447.72M0.36383,433 shs335,572 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTICCTI BioPharma0.00%0.00%0.00%0.00%+71.51%DYNDyne Therapeutics+4.23%-2.24%-11.93%+46.47%+119.12%TBPHTheravance Biopharma+1.28%-4.64%+6.05%-4.73%-18.17%Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ADYNDyne Therapeutics3.3842 of 5 stars4.61.00.00.02.24.20.6TBPHTheravance Biopharma2.0913 of 5 stars3.52.00.00.01.92.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTICCTI BioPharma2.00HoldN/AN/ADYNDyne Therapeutics3.14Buy$37.4347.12% UpsideTBPHTheravance Biopharma3.00Buy$20.50122.34% UpsideCurrent Analyst RatingsLatest TBPH, CTIC, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.003/6/2024DYNDyne TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $29.003/5/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.002/20/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ATBPHTheravance Biopharma$57.42M7.80N/AN/A$4.28 per share2.15Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/ADYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)Latest TBPH, CTIC, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/A2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTICCTI BioPharmaN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTICCTI BioPharmaN/A1.271.26DYNDyne TherapeuticsN/A2.532.53TBPHTheravance BiopharmaN/A5.395.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTICCTI BioPharma91.45%DYNDyne Therapeutics96.68%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipCTICCTI BioPharma7.61%DYNDyne Therapeutics20.77%TBPHTheravance Biopharma6.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableDYNDyne Therapeutics14186.18 million68.28 millionOptionableTBPHTheravance Biopharma35948.56 million45.21 millionOptionableTBPH, CTIC, and DYN HeadlinesSourceHeadlineTheravance Biopharma, Inc. Expected to Earn FY2024 Earnings of ($0.89) Per Share (NASDAQ:TBPH)americanbankingnews.com - April 18 at 2:00 AMZacks Research Analysts Reduce Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - April 17 at 5:38 PMTheravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71msn.com - April 17 at 5:14 PMQ1 2026 Earnings Estimate for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks Researchamericanbankingnews.com - April 17 at 2:24 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q1 2026 Earnings of $0.29 Per Share, Zacks Research Forecastsmarketbeat.com - April 16 at 7:44 AMBTIG Research Predicts Over 118% Rally for These 3 Stocksinvestorplace.com - April 15 at 2:19 PMStrength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?zacks.com - April 15 at 8:51 AMTheravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at BTIG Researchamericanbankingnews.com - April 14 at 3:34 AMVanguard Group Inc. Sells 379,627 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - April 12 at 4:08 AMTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024finance.yahoo.com - April 10 at 8:20 AMTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024prnewswire.com - April 10 at 6:00 AMWhy Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?zacks.com - March 27 at 12:36 PMTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04marketbeat.com - March 26 at 5:14 AMShort-Squeeze Showdown: 3 Stocks Ready to Crush the Skepticsinvestorplace.com - March 12 at 3:59 PMAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potentialmarkets.businessinsider.com - March 7 at 9:55 AMTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestonesmarkets.businessinsider.com - February 28 at 10:50 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:50 AMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - February 27 at 11:30 PMTheravance Biopharma Inc (TBPH)investing.com - February 27 at 1:29 PMTheravance's (TBPH) Q4 Earnings & Revenues Surpass Estimateszacks.com - February 27 at 12:51 PMBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharmamarkets.businessinsider.com - February 27 at 1:45 AMTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03Mmsn.com - February 26 at 8:44 PMTheravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimateszacks.com - February 26 at 6:26 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - February 26 at 4:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCTI BioPharmaNASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Dyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.